MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

NCT05286788 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Adamantinous Craniopharyngioma
Recurrent Adamantinomatous Craniopharyngioma

Interventions

DRUG: Binimetinib Oral Tablet [Mektovi]

Sponsor

Nationwide Children's Hospital

Collaborators

[object Object]